Literature DB >> 6256250

Abnormalities of serum cholinesterase isozyme in liver cirrhosis and hepatoma (Part II).

S Matsuzaki, K Iwamura, M Itakura, T Katsunuma.   

Abstract

The pattern of serum cholinesterase (ChE) isozyme appeared to be characteristically abnormal in liver cirrhosis and hepatoma. In liver cirrhosis an abnormal fast moving peak was observed in 92.5% of fifty three patients studied. Further, diminishing activities of ChE 3 and 4, accompanied by an emergence of weak bands with unusual rates of flow, were noted in 58.5%. The latter abnormality was always associated with the former one. The pattern in hepatoma was essentially the same with liver cirrhosis, though diversity of bands was also present in some cases. It was ascertained that these abnormalities was due to sialic acid content bound to the enzyme, but was not due to production of abnormal enzyme protein moiety. It was suggested by clinical analysis that the degree of the abnormality of the isozyme may be useful for the diagnosis and prognostic evaluation of liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6256250     DOI: 10.1007/bf02773757

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  24 in total

1.  Studies of cholinesterase activity. II. Serum cholinesterase in hepatitis and cirrhosis.

Authors:  R V LAMOTTA; H M WILLIAMS; H J WETSTONE
Journal:  Gastroenterology       Date:  1957-07       Impact factor: 22.682

2.  Measurement of serum cholinesterase activity in the study of diseases of the liver and biliary system.

Authors:  L J VORHAUS; H H SCUDAMORE; R M KARK
Journal:  Gastroenterology       Date:  1950-06       Impact factor: 22.682

3.  Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule.

Authors:  H R Gralnick; H Givelber; E Abrams
Journal:  N Engl J Med       Date:  1978-08-03       Impact factor: 91.245

4.  Dysfibrinogenemia associated with liver disease.

Authors:  J E Palascak; J Martinez
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

5.  Dysfibrinogenaemia associated with primary hepatoma.

Authors:  R Verhaeghe; B van Damme; A Molla; J Vermylen
Journal:  Scand J Haematol       Date:  1972

6.  Separation of serum cholinesterase isozymes by an improved polyacrylamide gel electrophoresis and its application for the study of liver diseases (Part I).

Authors:  S Matsuzaki; K Iwamura; T Katsunuma; H Kamiguchi
Journal:  Gastroenterol Jpn       Date:  1980

7.  Isolation and characterization of a novel vitamin B12-binding protein associated with hepatocellular carcinoma.

Authors:  R L Burger; S Waxman; H S Gilbert; C S Mehlman; R H Allen
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

8.  Acquired dysfibrinogenaemia in acute and chronic liver disease.

Authors:  D A Lane; M F Scully; D P Thomas; V V Kakkar; I L Woolf; R Williams
Journal:  Br J Haematol       Date:  1977-02       Impact factor: 6.998

9.  Characterization of sialytransferase in noncancerous and neoplastic human liver tissue.

Authors:  H A Ingraham; J A Alhadeff
Journal:  J Natl Cancer Inst       Date:  1978-12       Impact factor: 13.506

10.  The clinical and physiological implications of hepatoma B12-binding proteins.

Authors:  S Waxman; C K Liu; C Schreiber; L Helson
Journal:  Cancer Res       Date:  1977-06       Impact factor: 12.701

View more
  1 in total

1.  A case of familial hyper-cholinesterasemia associated with isozyme variant band.

Authors:  K Yamamoto; F Morito; M Motomura; H Kaneoka; T Sakai
Journal:  Gastroenterol Jpn       Date:  1986-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.